Literature DB >> 25245984

8q24 amplified segments involve novel fusion genes between NSMCE2 and long noncoding RNAs in acute myelogenous leukemia.

Yoshiaki Chinen, Natsumi Sakamoto, Hisao Nagoshi, Tomohiko Taki, Saori Maegawa, Shotaro Tatekawa, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Yosuke Matsumoto, Shigeo Horiike, Junya Kuroda, Masafumi Taniwaki.   

Abstract

The pathogenetic roles of 8q24 amplified segments in leukemic cells with double minute chromosomes remain to be verified. Through comprehensive molecular analyses of 8q24 amplicons in leukemic cells from an acute myelogenous leukemia (AML) patient and AML-derived cell line HL60 cells, we identified two novel fusion genes between NSMCE2 and long noncoding RNAs (lncRNAs), namely, PVT1-NSMCE2 and BF104016-NSMCE2. Our study suggests that 8q24 amplicons are associated with the emergence of aberrant chimeric genes between NSMCE2 and oncogenic lncRNAs, and also implicate that the chimeric genes involving lncRNAs potentially possess as-yet-unknown oncogenic functional roles.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245984      PMCID: PMC4176872          DOI: 10.1186/s13045-014-0068-2

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


To the Editor,

To gain insight into the role(s) of double minute chromosomes (dmins) in leukemia, we cytogenetically/molecularly analyzed 8q24 amplicons in patient-derived leukemic cells and AML-derived cell line (HL60) (See Additional file 1 for supplementary materials and methods). The patient was a 71-year-old female with AML (M2). The G-banding karyotype of leukemic cells was 47, XX, +mar [2]/48, XX, idem, +mar [6]/46, XX [7], containing two marker chromosomes (mars) from chromosome 8 (Figure 1a and b). DNA copy number analysis (CNA) revealed 13 high-level amplicons on 8q22.1-q24.2 (98.43 Mb-134.16 Mb) (Additional file 2: Table S1). SKY analysis of HL60 cells containing the 8q24 amplicons revealed that the representative karyotype was 44, X, der(5)t(5;17)(q11.2;q11.2), t(7;16;9)(q34;q24;p21), t(9;14)(q22;q22), +13, -15, -17, der(21)t(15;21)(q22;q21) [1]. CNA revealed several amplicons on 8q24.13-q24.12 (126.25 Mb-130.75 Mb) in the HL60 cells (Figure 2a and b). Consequently, three common amplicons were identified between 8q24.13-21 in the patient and the HL60 cells; i.e., the regions covering NSMCE2 (8q24.13), PVT1 (8q24.21) and CCDC26 (8q24.21) (Figures 1c and 2b). Further investigation revealed three fusion transcripts between PVT1 exon 1a and NSMCE2 exon 3 in the patient (Figure 1d and e), and a fusion gene between exon 6 of NSMCE2 and exon 1 of BF104016, a noncoding RNA sharing the sequence of CCDC26 exon 4 (Additional file 3: Figure S1) (Additional file 4: Table S2), in the HL60 cells (Figure 2c-e). Both the NSMCE2 and PVT1 genes were amplified and located in a micronucleus in the patient (Figure 1f-i), and the genomic junction of 5’-PVT1-NSMCE2-3’ was located within intron 1 of PVT1 and at 5’ upstream of exon 1 of NSMCE2 (Figure 1j and k) (Additional file 5: Figure S3). In the HL60 cells, amplification of 3’NSMCE2 and 5CCDC26 was co-localized on der(13)hsr(8), ins(2;8) and dmins (Figure 2e-h) (Additional file 5: Figure S3). Aberrant NSMCE2 transcripts were higher than normal NSMCE2 transcripts in the patient and the HL60 cells, while NSMCE2 protein expression did not correlate with normal or abnormal NSMCE2 transcripts among the leukemic patient cells or the HL60 cells, suggesting the presence of regulatory mechanisms other than transcription (Additional file 6: Figure S2).
Figure 1

Identification of in the leukemic patient cells. (a) G-banding analysis. Arrow indicates two marker chromosomes (mars). (b) SKY analysis for the patient identified two mars derived from chromosome 8 (arrows). (c) Copy number changes at 8q24 detected by high-resolution oligonucleotide array. NSMCE2, TRIB1, MYC, PVT1, CCDC26, GSDMC, and FAM49B are amplified. The direction of the arrows reflects the direction of gene transcription. NG: no gene. (d) Detection of three PVT1-NSMCE2 fusion transcripts by RT-PCR. Primers were P1S and NSMCE2-Ex4AS for 5'-PVT1-NSMCE2-3'. Lane Pt.1: leukemic cells from the patient; lane N: water; lane M: size marker. (e) Sequence analysis of NSMCE2 fusion transcript in the patient. (f) FISH finding of the patient using PVT1 probe. Multiple red signals indicate extrachromosomal amplification of 5’PVT1 on dmins. Co-localized red and green signals indicate normal PVT1. Inset shows 5’PVT1 amplification in a micronucleus equivalent of mar (arrow). (Additional file 5: Figure S3) (g) FISH finding from the patient using an NSMCE2 probe. Intense yellow signals indicate amplification of NSMCE2 on mars and co-localized red and green signals signify normal NSMCE2 on chromosome 8. Inset shows NSMCE2 amplification in a micronucleus equivalent of mar (arrow). (h and i) DAPI pictures of metaphase cells corresponding to (f) and (g). Arrows indicate mars. In metaphase, NSMCE2 amplification was detectable on mars. 5’PVT1 amplification were observed on dmins, however, PVT1 FISH probe sets could not identify mars because of the background dmins (f and h). (j) Results of LDI-PCR. Primers were NSM38374 and NSM38666 for 5'-PVT1-NSMCE2-3'. Lane Pt.1: leukemic cells from the patient; lane N: water; lane M: size marker. (Additional file 4: Table S2) (k) Genomic mapping of PVT1 and NSMCE2 exons and breakpoint. White vertical boxes represent exons; dotted line represents breakpoint of PVT1 and NSMCE2 in the patient detected by LDI-PCR. Horizontal line indicates the location of miRNAs.

Figure 2

Identification of in HL60. (a) Representative SKY karyotype of HL60 cells. Arrowheads indicate material inserted from chromosome 8 on ins(2;8) and der(13)hsr(8). Inset shows pseudocolor image of ins(2;8). (b) Copy number changes at 8q24 detected by high-resolution oligonucleotide array. NSMCE2, TRIB1, MYC, PVT1 and CCDC26 are amplified in HL60. The direction of the arrows reflects the direction of the gene transcription. NG: no gene. (c) Bubble PCR products detected by nested PCR using NVAMP1 and NSMCE2-Ex7AS for the first PCR, and NVAMP2 and NSM695 for the second. M: size marker. (d) Sequence analysis of NSMCE2 fusion transcript of HL60. (e) Detection of BF104016-NSMCE2 fusion transcripts by RT-PCR. Primers were BF104-1S and NSMCE2-Ex7AS for 5'-BF104016-NSMCE2-3'. Lanes N: water. (Additional file 4: Table S2) (f) FISH finding of HL60 using CCDC26 probe. Intense co-localized red and green signal indicates amplification of the CCDC26 gene on der(13)hsr(8) (arrowhead). A co-localized red and green signal is seen on ins(2;8) (arrow). Multiple green signals indicate amplification of the 5’CCDC26 gene on dmins. Co-localized red and green signals show normal CCDC26. (g) FISH finding of HL60 using NSMCE2 probe. Intense green signals indicate amplification of 3’NSMCE2 on der(13)hsr(8) (arrowhead) and ins(2;8) (arrow). Multiple red and green signals indicate amplification of the NSMCE2 gene on dmins. Co-localized red and green signals indicate normal chromosomal NSMCE2. (Additional file 5: Figure S3) (h and i) DAPI pictures of metaphase cells corresponding to (f) and (g). Arrow and arrowhead indicate ins(2;8) and der(13)hsr(8), respectively.

Identification of in the leukemic patient cells. (a) G-banding analysis. Arrow indicates two marker chromosomes (mars). (b) SKY analysis for the patient identified two mars derived from chromosome 8 (arrows). (c) Copy number changes at 8q24 detected by high-resolution oligonucleotide array. NSMCE2, TRIB1, MYC, PVT1, CCDC26, GSDMC, and FAM49B are amplified. The direction of the arrows reflects the direction of gene transcription. NG: no gene. (d) Detection of three PVT1-NSMCE2 fusion transcripts by RT-PCR. Primers were P1S and NSMCE2-Ex4AS for 5'-PVT1-NSMCE2-3'. Lane Pt.1: leukemic cells from the patient; lane N: water; lane M: size marker. (e) Sequence analysis of NSMCE2 fusion transcript in the patient. (f) FISH finding of the patient using PVT1 probe. Multiple red signals indicate extrachromosomal amplification of 5’PVT1 on dmins. Co-localized red and green signals indicate normal PVT1. Inset shows 5’PVT1 amplification in a micronucleus equivalent of mar (arrow). (Additional file 5: Figure S3) (g) FISH finding from the patient using an NSMCE2 probe. Intense yellow signals indicate amplification of NSMCE2 on mars and co-localized red and green signals signify normal NSMCE2 on chromosome 8. Inset shows NSMCE2 amplification in a micronucleus equivalent of mar (arrow). (h and i) DAPI pictures of metaphase cells corresponding to (f) and (g). Arrows indicate mars. In metaphase, NSMCE2 amplification was detectable on mars. 5’PVT1 amplification were observed on dmins, however, PVT1 FISH probe sets could not identify mars because of the background dmins (f and h). (j) Results of LDI-PCR. Primers were NSM38374 and NSM38666 for 5'-PVT1-NSMCE2-3'. Lane Pt.1: leukemic cells from the patient; lane N: water; lane M: size marker. (Additional file 4: Table S2) (k) Genomic mapping of PVT1 and NSMCE2 exons and breakpoint. White vertical boxes represent exons; dotted line represents breakpoint of PVT1 and NSMCE2 in the patient detected by LDI-PCR. Horizontal line indicates the location of miRNAs. Identification of in HL60. (a) Representative SKY karyotype of HL60 cells. Arrowheads indicate material inserted from chromosome 8 on ins(2;8) and der(13)hsr(8). Inset shows pseudocolor image of ins(2;8). (b) Copy number changes at 8q24 detected by high-resolution oligonucleotide array. NSMCE2, TRIB1, MYC, PVT1 and CCDC26 are amplified in HL60. The direction of the arrows reflects the direction of the gene transcription. NG: no gene. (c) Bubble PCR products detected by nested PCR using NVAMP1 and NSMCE2-Ex7AS for the first PCR, and NVAMP2 and NSM695 for the second. M: size marker. (d) Sequence analysis of NSMCE2 fusion transcript of HL60. (e) Detection of BF104016-NSMCE2 fusion transcripts by RT-PCR. Primers were BF104-1S and NSMCE2-Ex7AS for 5'-BF104016-NSMCE2-3'. Lanes N: water. (Additional file 4: Table S2) (f) FISH finding of HL60 using CCDC26 probe. Intense co-localized red and green signal indicates amplification of the CCDC26 gene on der(13)hsr(8) (arrowhead). A co-localized red and green signal is seen on ins(2;8) (arrow). Multiple green signals indicate amplification of the 5’CCDC26 gene on dmins. Co-localized red and green signals show normal CCDC26. (g) FISH finding of HL60 using NSMCE2 probe. Intense green signals indicate amplification of 3’NSMCE2 on der(13)hsr(8) (arrowhead) and ins(2;8) (arrow). Multiple red and green signals indicate amplification of the NSMCE2 gene on dmins. Co-localized red and green signals indicate normal chromosomal NSMCE2. (Additional file 5: Figure S3) (h and i) DAPI pictures of metaphase cells corresponding to (f) and (g). Arrow and arrowhead indicate ins(2;8) and der(13)hsr(8), respectively. The present findings are consistent with previous studies demonstrating that segmental genome amplification of 8q24 contains recurrent PVT1 fusion genes, which might be generated by chromothripsis [2,3]. Both lncRNAs, PVT1 and CCDC26, harbor retroviral integration sites and are transcribed into multiple splice forms [4-6]. PVT1 overexpression is induced by MYC or p53, contributing to suppression of apoptosis [7-9], whereas PVT1 produces six annotated microRNAs that have been implicated in oncogenesis [3,10,11]. The chimeric transcripts involving PVT1 may also regulate the expression of as-yet unspecified target genes through “enhancer-like functions” [12]. CCDC26 amplification has been also identified as a recurrent abnormality that is associated with the response to retinoic acid-induced differentiation in AML [1,11,13-16]. This study is the first to identify NSMCE2-associated fusion genes in AML [17-19]. Knockdown of NSMCE2 induces chromosomal instability and increases the frequency of chromosomal breakage and loss [20]. We speculate that NSMCE2 gene rearrangement may potentially influence its function. Collectively, our study identified novel PVT1-NSMCE2 and CCDC26-NSMCE2 fusion genes that may play functional roles in leukemia. Supplementary material information. CNAG analysis of the region between the MTDH and LRRC6 genes on 8q24 in patient 1 with marker chromosomes. Results show the genomic size of the eight amplified segments that were selected based on the existence of known genes within them and their approximate positions. Association between CCDC26 and BF104016 at 8q24.21. The scale indicates the region 8q24.21. White boxes and grey boxes indicate exons of CCDC26 and BF104016 on the genetic locus at 8q24.21, respecitively. Vertical black lines indicate exons on the CCDC26 isoform. According to the NCBI database, isoform 1 (BC070152.1) consists of four (1-2-3-4) exons, and isoform 2 (BC026098.1) consists of three (1a-3-4) exons. BF104016 consists of 2 exons. The sequence of BF104016 exon 2 is partly consistent with that of CCDC26 exon 4. ORF: hypothetical open reading frame. Sequences of the primers used in this study. Identification of breakpoints region at 8q24 by FISH. Upper panel: location of FISH probes shown as color bars and position of NSMCE2, TRIB1, MYC, and PVT1 genes at 8q24. Vertical black lines indicate exons of NSMCE2, PVT1, and BF104016. Lower panel: mapping of breakpoint in leukemic cells of patient 1 and HL60. Gray boxes indicate amplified regions detected. Expression of NSMCE2 in patient 1 and AML-derived cell lines. (a) NSMCE2 mRNA levels measured by RQ-PCR (n=3, mean ± SD). Theoretically, the NSMCE2 7-8 primer/probe can amplify both normal and aberrant NSMCE2 transcripts, while the NSMCE2 2-3 primer/probe set which can amplify only normal NSMCE2 transcript. NSMCE2 mRNA levels were normalized to β-actin and are relative to the control mRNA extracted from normal BM cells. NSMCE2 mRNA levels amplified by the NSMCE2 7-8 primer/probe set are higher than those amplified by the NSMCE2 2-3 primer/probe set in patient 1, HL60 and KG1 cells. (b) Protein analysis using the anti-NSMCE2 antibody in cells. Blot for β-actin was used as loading control. Lane 1: normal BM; lane 2: KG1; lane 3: HL60. (c and d) IHC analysis of NSMCE2 expression in BM of patient 1 (c) and normal BM (d). NSMCE2 expression of leukemic cells was not higher than that of normal BM cells. Monocytes and megakaryocytes showed strong positive signals in their cytoplasm.
  20 in total

1.  Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM.

Authors:  W Yin; A Rossin; J L Clifford; H Gronemeyer
Journal:  Oncogene       Date:  2006-01-30       Impact factor: 9.867

2.  Proviral integration site Mis-1 in rat thymomas corresponds to the pvt-1 translocation breakpoint in murine plasmacytomas.

Authors:  L Villeneuve; E Rassart; P Jolicoeur; M Graham; J M Adams
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

3.  Rearrangement of a DNA sequence homologous to a cell-virus junction fragment in several Moloney murine leukemia virus-induced rat thymomas.

Authors:  G Lemay; P Jolicoeur
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

4.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes.

Authors:  Paul A Northcott; David J H Shih; John Peacock; Livia Garzia; A Sorana Morrissy; Thomas Zichner; Adrian M Stütz; Andrey Korshunov; Jüri Reimand; Steven E Schumacher; Rameen Beroukhim; David W Ellison; Christian R Marshall; Anath C Lionel; Stephen Mack; Adrian Dubuc; Yuan Yao; Vijay Ramaswamy; Betty Luu; Adi Rolider; Florence M G Cavalli; Xin Wang; Marc Remke; Xiaochong Wu; Readman Y B Chiu; Andy Chu; Eric Chuah; Richard D Corbett; Gemma R Hoad; Shaun D Jackman; Yisu Li; Allan Lo; Karen L Mungall; Ka Ming Nip; Jenny Q Qian; Anthony G J Raymond; Nina T Thiessen; Richard J Varhol; Inanc Birol; Richard A Moore; Andrew J Mungall; Robert Holt; Daisuke Kawauchi; Martine F Roussel; Marcel Kool; David T W Jones; Hendrick Witt; Africa Fernandez-L; Anna M Kenney; Robert J Wechsler-Reya; Peter Dirks; Tzvi Aviv; Wieslawa A Grajkowska; Marta Perek-Polnik; Christine C Haberler; Olivier Delattre; Stéphanie S Reynaud; François F Doz; Sarah S Pernet-Fattet; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Wolfram Scheurlen; Charles G Eberhart; Michelle Fèvre-Montange; Anne Jouvet; Ian F Pollack; Xing Fan; Karin M Muraszko; G Yancey Gillespie; Concezio Di Rocco; Luca Massimi; Erna M C Michiels; Nanne K Kloosterhof; Pim J French; Johan M Kros; James M Olson; Richard G Ellenbogen; Karel Zitterbart; Leos Kren; Reid C Thompson; Michael K Cooper; Boleslaw Lach; Roger E McLendon; Darell D Bigner; Adam Fontebasso; Steffen Albrecht; Nada Jabado; Janet C Lindsey; Simon Bailey; Nalin Gupta; William A Weiss; László Bognár; Almos Klekner; Timothy E Van Meter; Toshihiro Kumabe; Teiji Tominaga; Samer K Elbabaa; Jeffrey R Leonard; Joshua B Rubin; Linda M Liau; Erwin G Van Meir; Maryam Fouladi; Hideo Nakamura; Giuseppe Cinalli; Miklós Garami; Peter Hauser; Ali G Saad; Achille Iolascon; Shin Jung; Carlos G Carlotti; Rajeev Vibhakar; Young Shin Ra; Shenandoah Robinson; Massimo Zollo; Claudia C Faria; Jennifer A Chan; Michael L Levy; Poul H B Sorensen; Matthew Meyerson; Scott L Pomeroy; Yoon-Jae Cho; Gary D Bader; Uri Tabori; Cynthia E Hawkins; Eric Bouffet; Stephen W Scherer; James T Rutka; David Malkin; Steven C Clifford; Steven J M Jones; Jan O Korbel; Stefan M Pfister; Marco A Marra; Michael D Taylor
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

5.  Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing.

Authors:  Peter J Campbell; Philip J Stephens; Erin D Pleasance; Sarah O'Meara; Heng Li; Thomas Santarius; Lucy A Stebbings; Catherine Leroy; Sarah Edkins; Claire Hardy; Jon W Teague; Andrew Menzies; Ian Goodhead; Daniel J Turner; Christopher M Clee; Michael A Quail; Antony Cox; Clive Brown; Richard Durbin; Matthew E Hurles; Paul A W Edwards; Graham R Bignell; Michael R Stratton; P Andrew Futreal
Journal:  Nat Genet       Date:  2008-04-27       Impact factor: 38.330

6.  Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.

Authors:  Yinghui Guan; Wen-Lin Kuo; Jackie L Stilwell; Hirokuni Takano; Anna V Lapuk; Jane Fridlyand; Jian-Hua Mao; Mamie Yu; Melinda A Miller; Jennifer L Santos; Steve E Kalloger; Joseph W Carlson; David G Ginzinger; Susan E Celniker; Gordon B Mills; David G Huntsman; Joe W Gray
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

7.  The identification of microRNAs in a genomically unstable region of human chromosome 8q24.

Authors:  Konrad Huppi; Natalia Volfovsky; Timothy Runfola; Tamara L Jones; Mark Mackiewicz; Scott E Martin; J Frederic Mushinski; Robert Stephens; Natasha J Caplen
Journal:  Mol Cancer Res       Date:  2008-02       Impact factor: 5.852

8.  Genes encoded within 8q24 on the amplicon of a large extrachromosomal element are selectively repressed during the terminal differentiation of HL-60 cells.

Authors:  Tetsuo Hirano; Fumio Ike; Takehide Murata; Yuichi Obata; Hiroyasu Utiyama; Kazunari K Yokoyama
Journal:  Mutat Res       Date:  2007-12-28       Impact factor: 2.433

9.  The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells.

Authors:  Letizia Carramusa; Flavia Contino; Arianna Ferro; Luigi Minafra; Giovanni Perconti; Agata Giallongo; Salvatore Feo
Journal:  J Cell Physiol       Date:  2007-11       Impact factor: 6.384

10.  Pvt1-encoded microRNAs in oncogenesis.

Authors:  Gabriele B Beck-Engeser; Amy M Lum; Konrad Huppi; Natasha J Caplen; Bruce B Wang; Matthias Wabl
Journal:  Retrovirology       Date:  2008-01-14       Impact factor: 4.602

View more
  22 in total

1.  Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element.

Authors:  Seung Woo Cho; Jin Xu; Ruping Sun; Maxwell R Mumbach; Ava C Carter; Y Grace Chen; Kathryn E Yost; Jeewon Kim; Jing He; Stephanie A Nevins; Suet-Feung Chin; Carlos Caldas; S John Liu; Max A Horlbeck; Daniel A Lim; Jonathan S Weissman; Christina Curtis; Howard Y Chang
Journal:  Cell       Date:  2018-05-03       Impact factor: 41.582

2.  Disappearance of double minute chromosomes with MYC amplification in relapsed acute myeloid leukemia after stem cell transplantation.

Authors:  Katsuya Yamamoto; Kimikazu Yakushijin; Keiji Kurata; Yukinari Sanada; Shinichiro Kawamoto; Hiroshi Matsuoka; Hironobu Minami
Journal:  Int J Hematol       Date:  2015-02-14       Impact factor: 2.490

3.  Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

Authors:  Julie W Reeser; Dorrelyn Martin; Jharna Miya; Esko A Kautto; Ezra Lyon; Eliot Zhu; Michele R Wing; Amy Smith; Matthew Reeder; Eric Samorodnitsky; Hannah Parks; Karan R Naik; Joseph Gozgit; Nicholas Nowacki; Kurtis D Davies; Marileila Varella-Garcia; Lianbo Yu; Aharon G Freud; Joshua Coleman; Dara L Aisner; Sameek Roychowdhury
Journal:  J Mol Diagn       Date:  2017-08-09       Impact factor: 5.568

Review 4.  Beyond mRNA: The role of non-coding RNAs in normal and aberrant hematopoiesis.

Authors:  Mark C Wilkes; Claire E Repellin; Kathleen M Sakamoto
Journal:  Mol Genet Metab       Date:  2017-07-25       Impact factor: 4.797

5.  Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma.

Authors:  Yosuke Matsumoto; Yoshiaki Chinen; Yuji Shimura; Hisao Nagoshi; Nana Sasaki; Ayako Muramatsu; Kodai Kuriyama; Muneo Ohshiro; Yoshiko Hirakawa; Toshiki Iwai; Hitoji Uchiyama; Tomohiko Taki; Shigeo Horiike; Junya Kuroda; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2019-11-04       Impact factor: 2.490

Review 6.  Perspectives of long non-coding RNAs in cancer.

Authors:  Arunagiri Kuha Deva Magendhra Rao; Thangarajan Rajkumar; Samson Mani
Journal:  Mol Biol Rep       Date:  2017-04-08       Impact factor: 2.316

7.  Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.

Authors:  Aparna Pallavajjala; Daehwan Kim; Tongbin Li; Gabriel Ghiaur; Richard J Jones; Kathleen H Burns; Steven L Salzberg; Yi Ning
Journal:  Leuk Lymphoma       Date:  2017-09-07

8.  NSMCE2 suppresses cancer and aging in mice independently of its SUMO ligase activity.

Authors:  Ariana Jacome; Paula Gutierrez-Martinez; Federica Schiavoni; Enrico Tenaglia; Paula Martinez; Sara Rodríguez-Acebes; Emilio Lecona; Matilde Murga; Juan Méndez; Maria A Blasco; Oscar Fernandez-Capetillo
Journal:  EMBO J       Date:  2015-10-06       Impact factor: 11.598

9.  Cancer RNA-Seq Nexus: a database of phenotype-specific transcriptome profiling in cancer cells.

Authors:  Jian-Rong Li; Chuan-Hu Sun; Wenyuan Li; Rou-Fang Chao; Chieh-Chen Huang; Xianghong Jasmine Zhou; Chun-Chi Liu
Journal:  Nucleic Acids Res       Date:  2015-11-23       Impact factor: 19.160

10.  Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia.

Authors:  Chengwu Zeng; Xibao Yu; Jing Lai; Lijiang Yang; Shaohua Chen; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2015-11-06       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.